UniQure N.V. (QURE)の価格はいくらですか

UniQure N.V. (QURE)の価格は$50.67です

UniQure N.V. (QURE)の時価総額は何ですか

UniQure N.V. (QURE)の時価総額は$3.51Bです

UniQure N.V.（QURE）PER（株価収益率）

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

年	P/E比率	変化
提供された日付のデータは十分ではありません。

年

P/E比率

変化

提供された日付のデータは十分ではありません。

企業	P/E比率	P/E比率の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
Moderna, Inc. MRNA.US	-7.93	-	US
CSL Limited CSL.AX	32.46	-	AU
Lonza Group AG LONN.SW	-	-	CH

企業

P/E比率

P/E比率の差

国